Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25410947 | 1.00 | GABRA1 (0.66) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL31366478 | 1.00 | GABRA1 (0.66) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25410939 | 1.00 | GABRA1 (0.66) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25412359 | 0.90 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL31366513 | 0.90 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25412361 | 0.90 | GABRA1 (0.71) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25411919 | 0.88 | CHRM1 (0.63) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25411923 | 0.88 | CHRM1 (0.63) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL25411916 | 0.88 | CHRM1 (0.63) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL31366492 | 0.88 | CHRM1 (0.63) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE | 2025-06-19 | — | — | US | disclosed |
| WO-2023172726-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197360-A1 | NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE | CUL4B, BRD4, CUL4A | GABRA1 2493/4885GABRA5 2307/4885GABRA3 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.